Xcell Therapeutics becomes first Korean company to export cell culture media to the U.S. and Germany...spurring global expansion 

Xcell Therapeutics said it has exported stem cell-specific media (serum-free chemistry) to Gemini Bioproducts in the U.S. and PeloBiotech in Germany.

The specific amount of the export was not disclosed due to non-disclosure. Considering the usual contracting method of global bio companies, a large-scale supply contract is expected to be signed after a period of checking the market response, according to the company.

In particular, the company has signed a co-labeling agreement with Gemini Bioproducts and is conducting joint promotions at ISCT, a global biotechnology conference being held in San Francisco through the 7th. The company also presented its technology for developing the world's first serum-free chemotaxis medium in a poster session.

An official from Xcell Therapeutics emphasized, "This export is the first case of a domestic bio company supplying advanced biomaterial products produced by its own technology to a leading overseas company." "This is of great significance in terms of securing small, medium, and large-scale technology sovereignty, which is currently being promoted at the pan-governmental level," he said. "In the U.S. and Europe, the importance of serum-free chemotactic media in the production of advanced biopharmaceuticals has long been emphasized, and the demand for serum-free chemotactic media is expected to continue to grow."

A biotech representative said, "The biggest topics in the advanced biotech industry are safety and affordability. Therefore, global companies are aiming for market leadership with media products that are safe from animal-derived contamination and can grow cells at a business-critical unit cost." "From this perspective, ExcelleraFutures' delivery to a global company is not only a recognition of its technology, but also significant for the company's quantitative growth in the future."

Xcell Therapeutics has developed the world's first cGMP-grade chemistry-free serum-free medium for stem cells (hMSCs). The company has already been recognized for its media technology both domestically and internationally. In particular, it owns and operates a GMP-grade production plant in Yongin that can produce 100,000 liters per year.

In particular, the company is expanding its product pipeline to include NK/T cell-specific media, DPC (hair follicle cell) specific media, exosome-specific media, and cultured meat-specific media through its own media development platform (XPorT).

Dr. Lee said, "Gemini and Pello are leading bioproduct distributors in the US and Germany. Both companies have ordered our products after rigorous in-house testing. We are currently in various discussions with the world's leading biological distributors regarding future business arrangements," said Dr. Lee. "We believe that our technology is key to leading and dominating the market."

Source: https://www.edaily.co.kr/news/read?newsId=02332086632326296&mediaCodeNo=257&OutLnkChk=Y